Table 1.
Item | Week 0 | Week 1 | Week 5 | Week 9 | Week 17 | ||
---|---|---|---|---|---|---|---|
PRIME-MD | √ | ||||||
Basic characteristicsa | √ | ||||||
Electrocardiogram | √ | √ | |||||
Informed consent | √ | ||||||
BDI-II | √ | √ | √ | √ | √ | ||
PHQ-9 | √ | √ | √ | √ | √ | ||
FIBSER | √ | √ | √ | √ | √ | ||
Blindness | √ | √ | √ | ||||
Treatment satisfaction | √ | √ | |||||
Allocation | √ | ||||||
Participant | K6 | √ | √ | √ | √ | ||
(Only those allocated to Kokoro-App) | (Only those allocated to Kokoro-App) | (Only those allocated to Kokoro-App) |
BDI-II Beck Depression Inventory-II, CRC clinical research coordinator, FIBSER Frequency, Intensity, and Burden of Side Effects Rating, K6 6-item self-report questionnaire to evaluate the severity of general psychological distress, PHQ-9 Patient Health Questionnaire-9, PRIME-MD Primary Care Evaluation of Mental Disorders
aBasic characteristics include sex, age, education, work status, marital status, age at first depressive episode, number of episodes, duration of the current depressive episode, information about treatment for current episode, and current history of physical illnesses